Sign in
4

Changes in Ownership

Karyopharm Therapeutics Inc. Filed Acc 0001209191-23-044040

EVP, Chief Development Officer sold 2,845 shares at $1.70 ($4,837)

  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Poulton Stuart · EVP, Chief Development Officer

Table I: Non-derivative

1 line
Date Transaction Shares Price Value Owned after D/I
2023-07-28 Sale : show line 1 in the form 10b5-1 −2,845 $1.70 $4,837 156,286 D
Open-market sales · 2,845 sh · avg $1.70 · $4,837
Loading xslF345X05/doc4.xml…